IBD (Inspire Corporate Bond ETF) Stock Analysis - Hedge Fund Holdings

Inspire Corporate Bond ETF (IBD) is a publicly traded the market company. As of May 21, 2026, IBD trades at $23.80 with a market cap of $0 and a P/E ratio of 0.00. IBD moved +0.00% today. Year to date, IBD is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces IBD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IBD stock?

Hedge funds tracked by Rallies that own IBD include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inspire Corporate Bond ETF.

IBD Key Metrics

Key financial metrics for IBD
MetricValue
Price$23.80
Market Cap$0
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$0.00
52-Week Low$0.00
Volume139.86K
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Top Hedge Funds Holding IBD

  • Citadel Advisors holds 173.99K shares of IBD, changed +127.08% as of Dec 31, 2024.

Latest IBD News

IBD Analyst Consensus

IBD analyst coverage data. Average price target: $0.00.

Common questions about IBD

Who owns IBD stock?
Hedge funds tracked by Rallies that own IBD include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inspire Corporate Bond ETF.
Does Rallies show 13F holders for IBD?
Yes. Rallies tracks hedge fund and 13F ownership data for IBD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IBD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IBD. It does not provide personalized investment advice.
IBD

IBD